1887

Abstract

The spread of antimicrobial resistance among members of the is a significant clinical threat. We report the treatment of pan-resistant bacteraemia with combination tigecycline and colistin in a 49-year-old male and review available therapeutic options. Despite a poor prognosis, the patient recovered, but remains colonized with the pan-resistant isolate.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.023010-0
2010-11-01
2020-09-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/11/1383.html?itemId=/content/journal/jmm/10.1099/jmm.0.023010-0&mimeType=html&fmt=ahah

References

  1. Agwuh K. N., MacGowan A. 2006; Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256–265 [CrossRef]
    [Google Scholar]
  2. CLSI 2009; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically ; Approved Standard. , 8th edn.M07–A08 Wayne, PA: Clinical and Laboratory Standards Institute;
  3. Cunha B. A. 2009; Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 47:1613 [CrossRef]
    [Google Scholar]
  4. Elemam A., Rahimian J., Mandell W. 2009; Infection with pan-resistant Klebsiella pneumoniae : a report of 2 cases and a brief review of the literature. Clin Infect Dis 49:271–274 [CrossRef]
    [Google Scholar]
  5. Falagas M. E., Kastoris A. C., Kapaskelis A. M., Karageorgopoulos D. E. 2010; Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10:43–50 [CrossRef]
    [Google Scholar]
  6. Isenberg H. D. 1992 Clinical Microbiology Procedures Handbook Washington, DC: American Society for Microbiology;
    [Google Scholar]
  7. Kelesidis T., Karageorgopoulos D. E., Kelesidis I., Falagas M. E. 2008; Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62:895–904 [CrossRef]
    [Google Scholar]
  8. Kitchel B., Rasheed J. K., Patel J. B., Srinivasan A., Navon-Venezia S., Carmeli Y., Brolund A., Giske C. G. 2009; Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 53:3365–3370 [CrossRef]
    [Google Scholar]
  9. Kochar S., Sheard T., Sharma R., Hui A., Tolentino E., Allen G., Landman D., Bratu S., Augenbraun M., Quale J. 2009; Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae . Infect Control Hosp Epidemiol 30:447–452 [CrossRef]
    [Google Scholar]
  10. Le J., Castanheira M., Burgess D. S., McKee B., Iqbal R., Jones R. N. 2010; Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach. California. J Clin Microbiol 48:623–625 [CrossRef]
    [Google Scholar]
  11. Nordmann P., Cuzon G., Naas T. 2009; The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236 [CrossRef]
    [Google Scholar]
  12. Palacios G., Hornig M., Cisterna D., Savji N., Bussetti A., Kapoor V., Hui J., Tokarz R., Briese T. other authors 2009; Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE 4:e8540 [CrossRef]
    [Google Scholar]
  13. Perez F., Endimiani A., Ray A. J., Decker B. K., Wallace C. J., Hujer K. M., Ecker D. J., Adams M. D., Toltzis P. other authors 2010; Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 65:1807–1818 [CrossRef]
    [Google Scholar]
  14. Scheetz M. H., Qi C., Warren J. R., Postelnick M. J., Zembower T., Obias A., Noskin G. A. 2007; In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii . Antimicrob Agents Chemother 51:1621–1626 [CrossRef]
    [Google Scholar]
  15. Vasilev K., Reshedko G., Orasan R., Sanchez M., Teras J., Babinchak T., Dukart G., Cooper A., Dartois N. other authors 2008; A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae . J Antimicrob Chemother 62:i29–i40 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.023010-0
Loading
/content/journal/jmm/10.1099/jmm.0.023010-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error